Human Reproduction Update, Vol.2, No.2 pp.162-171, 1996
© European Society of Human Reproduction and Embryology 1996; all rights reserved
Recombinant follicle stimulating hormone (rFSH; Puregon) in assisted reproduction: More oocytes, more pregnancies. Results from five comparative studies
NV Organon, PO Box 20, 5340 BH Oss, Netherlands 0 Corresponding author
Abstract
The clinical assessment of recombinant follicle stimulating hormone (rFSH; Puregon) in assisted reproduction technologies such as in-vitro fertilization (IVF) has probably been the most extensive clinical trial programme ever performed for the evaluation of a new fertility drug. It started with a pilot study to evaluate the potential of rFSH to stimulate the ovaries in the absence of luteinizing hormone (LH) - using various gonadotrophin-releasing hormone (GnRH) agonists. After it became clear that FSH-induced steroidogenesis was not jeopardized even after severe pituitary supression, comparisons between rFSH and urinary FSH or human menopausal gonadotrophins were made using different GnRH agonists or no agonists at all. In addition, the effects of the route of administration (s.c. or i.m.) were assessed. The study with the strongest statistical power to truly assess clinically relevant differences between rFSH and urinary FSH included ~1000 patient cycles. It indicated that after rFSH treatment, significantly more oocytes were retrieved, more embryos obtained and, as a result, more pregnancies achieved when the results of the cryoprogramme were included.
Keywords: IVF/recombinant FSH/urinary FSH
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H. Al-Inany, M. Aboulghar, R. Mansour, and G. Serour Meta-analysis of recombinant versus urinary-derived FSH: an update Hum. Reprod., February 1, 2003; 18(2): 305 - 313. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. De Sutter, J. Gerris, and M. Dhont A health-economic decision-analytic model comparing double with single embryo transfer in IVF/ICSI Hum. Reprod., November 1, 2002; 17(11): 2891 - 2896. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.E.F. Zwart-van Rijkom, F.J. Broekmans, and H.G.M. Leufkens From HMG through purified urinary FSH preparations to recombinant FSH: a substitution study Hum. Reprod., April 1, 2002; 17(4): 857 - 865. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Sykes, H. J. Out, S. J. Palmer, and J. v. Loon The cost-effectiveness of IVF in the UK: a comparison of three gonadotrophin treatments Hum. Reprod., December 1, 2001; 16(12): 2557 - 2562. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. T. Baird Is there a place for different isoforms of FSH in clinical medicine?: IV. The clinician's point of view Hum. Reprod., July 1, 2001; 16(7): 1316 - 1318. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. H. Y. Ng, E. Y. L. Lau, W. S. B. Yeung, and P. C. Ho HMG is as good as recombinant human FSH in terms of oocyte and embryo quality: a prospective randomized trial Hum. Reprod., February 1, 2001; 16(2): 319 - 325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Dor, D. Bider, A. Shulman, J. Levron, S. Shine, S. Mashiach, and J. Rabinovici Effects of gonadotrophin-releasing hormone agonists on human ovarian steroid secretion in vivo and in vitro--results of a prospective, randomized in-vitro fertilization study Hum. Reprod., June 1, 2000; 15(6): 1225 - 1230. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R.E. Felberbaum, C. Albano, M. Ludwig, H. Riethmuller-Winzen, M. Grigat, P. Devroey, and K. Diedrich Ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of the GnRH antagonist Cetrorelix according to the multiple dose protocol: a prospective uncontrolled phase III study Hum. Reprod., May 1, 2000; 15(5): 1015 - 1020. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Rose, R. E. Gaines Das, and A. H. Balen Definition and Measurement of Follicle Stimulating Hormone Endocr. Rev., February 1, 2000; 21(1): 5 - 22. [Abstract] [Full Text]
|
|
|
|
|
|
J. Harlin, G. Csemiczky, H. Wramsby, and G. Fried Recombinant follicle stimulating hormone in in-vitro fertilization treatment--clinical experience with follitropin alpha and follitropin beta Hum. Reprod., February 1, 2000; 15(2): 239 - 244. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Daya and J. Gunby Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction Hum. Reprod., September 1, 1999; 14(9): 2207 - 2215. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. I Meniru Is Puregon a `good' or `super' drug? Hum. Reprod., June 1, 1999; 14(6): 1409 - 1411. [Full Text] [PDF]
|
|
|
|
|
|
A. H. Balen, C. J. Hayden, and A. J. Rutherford Clinical efficacy of recombinant gonadotrophins Hum. Reprod., June 1, 1999; 14(6): 1411 - 1417. [Full Text] [PDF]
|
|
|
|
|
|
F. Raga, F. Bonilla-Musoles, E.M. Casan, and F. Bonilla Recombinant follicle stimulating hormone stimulation in poor responders with normal basal concentrations of follicle stimulating hormone and oestradiol: improved reproductive outcome Hum. Reprod., June 1, 1999; 14(6): 1431 - 1434. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L.G. Mantovani, A. Belisari, and T.D. Szucs Pharmaco-economic aspects of in-vitro fertilization in Italy Hum. Reprod., April 1, 1999; 14(4): 953 - 958. [Abstract] [Full Text] [PDF]
|
|